Diffusion Pharmaceuticals Inc DFFN shares are trading lower by 20.83% at $0.21 after the company announced a 1-for-50 reverse stock split.
Diffusion Pharmaceuticals says the reverse stock split is expected to become effective at 5:59 p.m. ET on Apr. 18. The company's common stock is expected to commence trading on the Nasdaq Capital Market on a post-split basis at the opening of the market on Apr. 19, pending confirmation by the Depository Trust Company and Nasdaq.
See Also: Why DiDi Global Stock Is Falling
Diffusion Pharmaceuticals is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy.
According to data from Benzinga Pro, Diffusion Pharmaceuticals has a 52-week high of $0.86 and a 52-week low of $0.20.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.